Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 15/20 | 0.75 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.41 |
| ▸ | ACACA | Q13085 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL867040 | 0.89 | MGLL (0.67) | MGLLFAAHHPGDACACA | |
| SCHEMBL865719 | 0.88 | MGLL (0.62) | MGLLFAAHHPGD | |
| SCHEMBL912553 | 0.86 | MGLL (1.00) | MGLLFAAHHPGD | |
| SCHEMBL868410 | 0.81 | MGLL (0.77) | MGLLFAAHHPGD | |
| SCHEMBL14647927 | 0.80 | MGLL (0.85) | MGLLFAAHHPGD | |
| SCHEMBL911594 | 0.79 | MGLL (0.86) | MGLLFAAHHPGDACACA | |
| SCHEMBL698708 | 0.79 | MGLL (0.79) | MGLLFAAHHPGD | |
| SCHEMBL911129 | 0.79 | MGLL (0.79) | MGLLFAAHHPGD | |
| SCHEMBL145465 | 0.78 | MGLL (0.85) | MGLLFAAHHPGD | |
| SCHEMBL911622 | 0.77 | MGLL (1.00) | MGLLFAAHHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637498-B2 | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, PNLIP, LIPA | MGLL 6/4885FAAH 46/4885HPGD 909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.